Abstract
Background and aims: Alpha-1 antitrypsin (AAT) is a major protease inhibitor produced by hepatocytes. The most relevant AAT mutation giving rise to AAT deficiency (AATD), the ‘Pi*Z’ variant, causes harmful AAT protein accumulation in the liver, shortage of AAT in the systemic circulation and thereby predisposes to liver and lung injury. Although intravenous AAT augmentation constitutes an established treatment of AATD-associated lung disease, its impact on the liver is unknown.
Methods: Liver-related parameters were assessed in a multinational cohort of 760 adults with severe AATD (Pi*ZZ genotype) and available liver phenotyping, of whom 344 received augmentation therapy and 416 did not. Liver fibrosis was evaluated non-invasively via the serum test AST-to-platelet ratio index (APRI) as well as via transient elastography-based liver stiffness measurement (LSM). Histological parameters were compared in 15 Pi*ZZ adults with and 35 without augmentation.
Results: Compared to non-augmented subjects, augmented Pi*ZZ individuals displayed lower serum liver enzyme levels (AST 71 vs. 75 % ULN, P
Conclusion: The first evaluation of AAT augmentation on the Pi*ZZ-related liver disease indicates liver safety of a widely used treatment for AATD-associated lung disease. Prospective studies are needed to confirm the beneficial effects and to demonstrate the potential efficacy of exogenous AAT in patients with Pi*ZZ-associated liver disease.
Methods: Liver-related parameters were assessed in a multinational cohort of 760 adults with severe AATD (Pi*ZZ genotype) and available liver phenotyping, of whom 344 received augmentation therapy and 416 did not. Liver fibrosis was evaluated non-invasively via the serum test AST-to-platelet ratio index (APRI) as well as via transient elastography-based liver stiffness measurement (LSM). Histological parameters were compared in 15 Pi*ZZ adults with and 35 without augmentation.
Results: Compared to non-augmented subjects, augmented Pi*ZZ individuals displayed lower serum liver enzyme levels (AST 71 vs. 75 % ULN, P
Conclusion: The first evaluation of AAT augmentation on the Pi*ZZ-related liver disease indicates liver safety of a widely used treatment for AATD-associated lung disease. Prospective studies are needed to confirm the beneficial effects and to demonstrate the potential efficacy of exogenous AAT in patients with Pi*ZZ-associated liver disease.
| Original language | English |
|---|---|
| Journal | Clinical Gastroenterology and Hepatology |
| Early online date | 15 Sept 2023 |
| DOIs | |
| Publication status | E-pub ahead of print - 15 Sept 2023 |
Keywords
- Fibroscan
- Pi*Z
- liver fibrosis
- SERPINA1
- alpha-1 antitrypsin deficiency
Fingerprint
Dive into the research topics of 'Alpha-1 antitrypsin (AAT) augmentation and the liver phenotype of adults with AAT deficiency (genotype Pi*ZZ)'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver